SCHEMBL6792592

SCHEMBL6792592

CC(=O)N1CC(CCN2CCC(c3ccc(Cl)c(Cl)c3)CC2)c2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.52
HTR1A P08908 1/20 0.52
HTR2A P28223 1/20 0.52
KCNH2 Q12809 3/20 0.43
CCR2 P41597 2/20 0.41
NOTUM Q6P988 1/20 0.41
DRD4 P21917 1/20 0.40
MCHR1 Q99705 2/20 0.39
SLC18A3 Q16572 1/20 0.39
SLC6A4 P31645 2/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A3 Q01959 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
ADRA1A P35348 1/20 0.38
TACR2 P21452 3/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11839176 0.87 DRD2 (0.57) DRD2HTR1AHTR2ANOTUMSLC18A3
SCHEMBL6790341 0.86 DRD2 (0.55) DRD2HTR1AHTR2AKCNH2NOTUM
SCHEMBL28752384 0.83 DRD2 (0.55) DRD2HTR1AHTR2AKCNH2NOTUM
SCHEMBL6794572 0.83 DRD2 (0.59) DRD2HTR1AHTR2ANOTUMDRD4
SCHEMBL11823970 0.82 DRD2 (0.52) DRD2HTR1AHTR2ACCR2NOTUM
SCHEMBL3958993 0.82 DRD2 (0.51) DRD2HTR1AHTR2AKCNH2NOTUM
SCHEMBL9014380 0.82 KCNH2 (0.48) DRD2HTR1AHTR2AKCNH2CCR2
SCHEMBL9014725 0.78 KCNH2 (0.63) DRD2HTR1AHTR2AKCNH2DRD4
SCHEMBL9014652 0.78 KCNH2 (0.48) DRD2HTR1AHTR2AKCNH2SLC6A4
SCHEMBL6789252 0.77 HTR1A (0.47) DRD2HTR1AHTR2ANOTUMSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040044007-A1 Indoline derivatives H. LUNDBECK A/S (DK) 2004-03-04 US claimed
EP-1345921-A1 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS H. Lundbeck A/S (DK) 2003-09-24 EP claimed
WO-2002051833-A1 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS H. LUNDBECK A/S (DK) 2002-07-04 WO claimed
US-20040044007-A1 Indoline derivatives H. LUNDBECK A/S (DK) 2004-03-04 US disclosed
EP-1345921-A1 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS H. Lundbeck A/S (DK) 2003-09-24 EP disclosed
WO-2002051833-A1 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS H. LUNDBECK A/S (DK) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044007-A1 Indoline derivatives CNR1, GRIN2C, HTR3C DRD2 43/4885HTR1A 7/4885HTR2A 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.